Summary
“More importantly than ever, a good product development and risk-based approach is going to be critical.”
In this episode of the Let's Talk Risk Podcast, Naveen Agarwal and Michael Nilo discuss the current state of the FDA amidst significant staff cuts and organizational chaos. They explore the implications for regulatory affairs professionals, t…
Listen to this episode with a 7-day free trial
Subscribe to Let's Talk Risk! to listen to this post and get 7 days of free access to the full post archives.
